Abstract
Although novel anticancer drugs are being developed intensively, anthracyclines remain the gold standard in the treatment of acute myeloid leukaemia (AML). The reductive conversion of daunorubicin (Dau) to less active daunorubicinol (Dau-ol) is an important mechanism that contributes to the development of pharmacokinetic anthracycline resistance. Dau is a key component in many AML regimes, in which it is combined with many drugs, including all-trans-retinoic acid (ATRA), cytarabine, cladribine and prednisolone. In the present study, we investigated the influence of these anticancer drugs on the reductive Dau metabolism mediated by the aldo–keto reductases AKR1A1, 1B10, 1C3, and 7A2 and carbonyl reductase 1 (CBR1). In incubation experiments with recombinant enzymes, cladribine and cytarabine did not significantly inhibit the activity of the tested enzymes. Prednisolone inhibited AKR1C3 with an IC50 of 41.73 µM, while ATRA decreased the activity of AKR1B10 (IC50 = 78.33 µM) and AKR1C3 (IC50 = 1.17 µM). Subsequent studies showed that AKR1C3 inhibition mediated by ATRA exhibited tight binding (Kiapp = 0.54 µM). Further, the combination of 1 µM ATRA with different concentrations of Dau demonstrated synergistic effects in HCT116 and KG1a human cells expressing AKR1C3. Our results suggest that ATRA-mediated inhibition of AKR1C3 can contribute to the mechanisms that are hidden beyond the beneficial clinical outcome of the ATRA–Dau combination.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ades L, Chevret S, Raffoux E et al (2013) Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients. Am J Hematol 88(7):556–559. https://doi.org/10.1002/ajh.23451
Ahmad Tali M, Bashir Y, Bhat S et al (2015) Pseudotumour cerebri in acute promyelocytic leukemia on treatment with all-trans-retinoic acid (ATRA)—an experience from a tertiary care centre. Malays J Pathol 37(2):141–144
Bains OS, Grigliatti TA, Reid RE, Riggs KW (2010) Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin. J Pharmacol Exp Ther 335(3):533–545. https://doi.org/10.1124/jpet.110.173179
Bains OS, Szeitz A, Lubieniecka JM et al (2013) A correlation between cytotoxicity and reductase-mediated metabolism in cell lines treated with doxorubicin and daunorubicin. J Pharmacol Exp Ther 347(2):375–387. https://doi.org/10.1124/jpet.113.206805
Bashar T, Apu MNH, Mostaid MS, Islam MS, Hasnat A (2018) Pharmacokinetics and bioavailability study of a prednisolone tablet as a single oral dose in Bangladeshi healthy volunteers. Dose Response 16(3):1559325818783932. https://doi.org/10.1177/1559325818783932
Bayat Mokhtari R, Homayouni TS, Baluch N et al (2017) Combination therapy in combating cancer. Oncotarget 8(23):38022–38043. https://doi.org/10.18632/oncotarget.16723
Birtwistle J, Hayden RE, Khanim FL et al (2009) The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis. Mutat Res 662(1–2):67–74. https://doi.org/10.1016/j.mrfmmm.2008.12.010
Blat Y (2010) Non-competitive inhibition by active site binders. Chem Biol Drug Des 75(6):535–540. https://doi.org/10.1111/j.1747-0285.2010.00972.x
Bogason A, Quartino AL, Lafolie P et al (2011) Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia. Br J Clin Pharmacol 71(4):514–521. https://doi.org/10.1111/j.1365-2125.2010.03894.x
Boucek RJ, Olson RD, Brenner DE, Ogunbunmi EM, Inui M, Fleischer S (1987) The major metabolite of Doxorubicin is a potent inhibitor of membrane-associated ion pumps—a correlative study of cardiac-muscle with isolated membrane-fractions. J Biol Chem 262(33):15851–15856
Castaigne S, Lefebvre P, Chomienne C et al (1993) Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia. Blood 82(12):3560–3563
Chen EC, Fathi AT, Brunner AM (2018) Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML. Oncol Targets Ther 11:3425–3434. https://doi.org/10.2147/OTT.S141212
Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70(2):440–446. https://doi.org/10.1158/0008-5472.CAN-09-1947
Copeland RA (2005) Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists. Wiley, Hoboken
Czeczuga-Semeniuk E, Wolczynski S, Dabrowska M, Dzieciol J, Anchim T (2004) The effect of doxorubicin and retinoids on proliferation, necrosis and apoptosis in MCF-7 breast cancer cells. Folia Histochem Cytobiol 42(4):221–227
Desmond J, Mountford J, Drayson M et al (2003) The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs. Cancer Res 63(2):505–512
Donovan M, Olofsson B, Gustafson A-L, Dencker L, Eriksson U (1995) The cellular retinoic acid binding proteins. J Steroid Biochem Mol Biol 53(1–6):459–465. https://doi.org/10.1016/0960-0760(95)00092-e
Endo S, Matsunaga T, Ohta C et al (2011) Roles of rat and human aldo-keto reductases in metabolism of farnesol and geranylgeraniol. Chem Biol Interact 191(1–3):261–268. https://doi.org/10.1016/j.cbi.2010.12.017
Gueddari-Pouzols N, Duriez P, Chomienne C, Trussardi A, Jardillier JC (2001) Interaction between mevalonate pathway and retinoic acid-induced differentiation. J Biomed Biotechnol 1(3):108–113. https://doi.org/10.1155/S1110724301000183
Hofman J, Buncek M, Haluza R, Streinz L, Ledvina M, Cigler P (2013) In vitro transfection mediated by dendrigraft poly(l-lysines): the effect of structure and molecule size. Macromol Biosci 13(2):167–176. https://doi.org/10.1002/mabi.201200303
Hofman J, Malcekova B, Skarka A, Novotna E, Wsol V (2014) Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3. Toxicol Appl Pharmacol 278(3):238–248. https://doi.org/10.1016/j.taap.2014.04.027
Holowiecki J, Grosicki S, Giebel S et al (2012) Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol 30(20):2441–2448. https://doi.org/10.1200/JCO.2011.37.1286
Jez JM, Bennett MJ, Schlegel BP, Lewis M, Penning TM (1997) Comparative anatomy of the aldo-keto reductase superfamily. Biochem J 326(Pt 3):625–636. https://doi.org/10.1042/bj3260625
Jing J, Nelson C, Paik J, Shirasaka Y, Amory JK, Isoherranen N (2017) Physiologically based pharmacokinetic model of all-trans-retinoic acid with application to cancer populations and drug interactions. J Pharmacol Exp Ther 361(2):246–258. https://doi.org/10.1124/jpet.117.240523
Komoto J, Yamada T, Watanabe K, Takusagawa F (2004) Crystal structure of human prostaglandin F synthase (AKR1C3). Biochemistry 43(8):2188–2198. https://doi.org/10.1021/bi036046x
Lefebvre P, Thomas G, Gourmel B et al (1991) Pharmacokinetics of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Leukemia 5(12):1054–1058
Malani D, Murumagi A, Yadav B et al (2017) Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML. Leukemia 31(5):1187–1195. https://doi.org/10.1038/leu.2016.314
Mirza N, Fishman M, Fricke I et al (2006) All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 66(18):9299–9307. https://doi.org/10.1158/0008-5472.CAN-06-1690
Muindi J, Frankel SR, Miller WH Jr et al (1992) Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid “resistance” in patients with acute promyelocytic leukemia. Blood 79(2):299–303
Nishizawa M, Nakajima T, Yasuda K et al (2000) Close kinship of human 20α-hydroxysteroid dehydrogenase gene with three aldo-keto reductase genes. Genes Cells 5(2):111–125. https://doi.org/10.1046/j.1365-2443.2000.00310.x
Novotna E, Bukum N, Hofman J et al (2018) Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): a promising therapeutic target for cancer treatment. Biochem Pharmacol 156:22–31. https://doi.org/10.1016/j.bcp.2018.08.001
Olson RD, Mushlin PS, Brenner DE et al (1988) Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci USA 85(10):3585–3589. https://doi.org/10.1073/pnas.85.10.3585
Osman AEG, Anderson J, Churpek JE et al (2018) Treatment of acute promyelocytic leukemia in adults. J Oncol Pract 14(11):649–657. https://doi.org/10.1200/JOP.18.00328
Pluta A, Robak T, Wrzesien-Kus A et al (2017) Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial. Am J Hematol 92(4):359–366. https://doi.org/10.1002/ajh.24654
Sanz MA, Martin G, Gonzalez M et al (2004) Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 103(4):1237–1243. https://doi.org/10.1182/blood-2003-07-2462
Skarka A, Skarydova L, Stambergova H, Wsol V (2011) Anthracyclines and their metabolism in human liver microsomes and the participation of the new microsomal carbonyl reductase. Chem Biol Interact 191(1–3):66–74. https://doi.org/10.1016/j.cbi.2010.12.016
Skarydova L, Nobilis M, Wsol V (2013) Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro. Xenobiotica 43(4):346–354. https://doi.org/10.3109/00498254.2012.720048
Skarydova L, Zivna L, Xiong G, Maser E, Wsol V (2009) AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. Chem Biol Interact 178(1–3):138–144. https://doi.org/10.1016/j.cbi.2008.10.015
Skribek H, Otvos R, Flaberg E et al (2010) Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin. Exp Hematol 38(12):1219–1230. https://doi.org/10.1016/j.exphem.2010.09.001
Sorf A, Novotna E, Hofman J et al (2019) Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: interaction with carbonyl-reducing enzymes and ABC transporters. Biochem Pharmacol 163:290–298. https://doi.org/10.1016/j.bcp.2019.02.035
Sun R, Liu Y, Li SY et al (2015) Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells. Biomaterials 37:405–414. https://doi.org/10.1016/j.biomaterials.2014.10.018
Suzuki-Yamamoto T, Nishizawa M, Fukui M et al (1999) cDNA cloning, expression and characterization of human prostaglandin F synthase. FEBS Lett 462(3):335–340. https://doi.org/10.1016/s0014-5793(99)01551-3
Tallman MS, Andersen JW, Schiffer CA et al (1997) All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337(15):1021–1028. https://doi.org/10.1056/NEJM199710093371501
Testi AM, Pession A, Diverio D et al (2018) Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. Blood 132(4):405–412. https://doi.org/10.1182/blood-2018-03-836528
Toma S, Maselli G, Dastoli G, De Elena F, Raffo P (1997) Synergistic effect between doxorubicin and a low dose of all-trans-retinoic acid in MCF-7 breast cancer cell line. Cancer Lett 116(1):103–110. https://doi.org/10.1016/s0304-3835(97)00169-9
Tu H, Powers JP, Liu J et al (2008) Distinctive molecular inhibition mechanisms for selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1. Bioorg Med Chem 16(19):8922–8931. https://doi.org/10.1016/j.bmc.2008.08.065
Vadlapatla RK, Vadlapudi AD, Pal D, Mitra AK (2013) Mechanisms of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transporters and metabolizing enzymes. Curr Pharm Des 19(40):7126–7140. https://doi.org/10.2174/13816128113199990493
Wilson DK, Tarle I, Petrash JM, Quiocho FA (1993) Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat. Proc Natl Acad Sci USA 90(21):9847–9851. https://doi.org/10.1073/pnas.90.21.9847
Acknowledgements
This work was supported by the InoMed project (Reg. No. CZ.02.1.01/0.0/0.0/18_069/0010046) co-funded by the European Union, the Grant Agency of Charles University (project no. 1006218 and SVV 260 550) and the Czech Science Foundation (project No. 20-20414Y). Language editing was provided by Elsevier.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Novotná, E., Morell, A., Büküm, N. et al. Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens?. Arch Toxicol 94, 3059–3068 (2020). https://doi.org/10.1007/s00204-020-02818-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-020-02818-y